News
News

The latest updates from AFAR.

Grantees in the News: Kapahi and Killiea research on unrecognized potential drug targets to treat elevated Urinalysis levels in PLOS Genetics

Aug 29
2019

Grantees in the News: Kapahi and Killiea research on unrecognized potential drug targets to treat elevated Urinalysis levels in PLOS Genetics View MoreBACK

On August 15, PLOS Genetics published research co-authored by AFAR experts Pankaj Kapahi, PhD, and David Killilea, PhD that determined previously unrecognized potential drug targets to treat elevated Urinalysis levels and associated pathologies such as gout or UA kidney stones, with the potential additional benefit of extending human healthspan.

Dr. Kapahi is a 2001 Glenn/AFAR Postdoctoral Fellowship Program for Translational Research on Aging recipient, a 2006 Glenn/AFAR Breakthroughs in Gerontology (BIG) Award recipient, and a 2011 Ellison/AFAR Julie Martin Midcareer Award in Aging Research recipient. He is also a Professor at the Buck Institute for Research on Aging at the University of Southern California.

Dr. Killilea is a 1999 Glenn/AFAR Scholarships for Research in the Biology of Aging recipient, and a 2003 Glenn/AFAR Postdoctoral Fellowship Program for Translational Research on Aging recipient, as well as the Director of the CHORI Elemental Analysis Facility at the Children’s Hospital Oakland Research Institute.

Read the research, “A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in Drosophila melanogaster,” here.





View MoreBACK TO TOP